<DOC>
	<DOCNO>NCT01682811</DOCNO>
	<brief_summary>GENERAL OBJECTIVE The general objective ass safety efficacy photodynamic therapy ( PDT ) treatment neurofibromatosis 1 ( NF1 ) tumor skin . SPECIFIC OBJECTIVE This light dose escalation pilot study determine safety efficacy PDT use 5-aminolevulinic acid ( ALA ) 630 nm light treatment benign dermal neurofibroma . Specifically , primary goal current study determine maximum tolerable light dos administer subject undergoing topical photoillumination photodynamic therapy standard application Levulan Kerastick ( ALA ) Topical Solution .</brief_summary>
	<brief_title>Photodynamic Therapy ( PDT ) Benign Dermal Neurofibromas ( NF1 )</brief_title>
	<detailed_description>STUDY DESIGN This protocol Phase I light dose escalation pilot study determine safety , secondarily , efficacy PDT use Levulan 630 nm light treatment benign dermal neurofibroma . This protocol represent first two part plan three part study include pediatric adult subject . Part 1 consist study penetration uptake PS neurofibroma schedule excision . These tumor excise therapeutic reason unrelated study , study place burden subject 3-24 hr incubation Levulan tumor prior excision . The primary hypothesis test whether Levulan accumulate , convert PpIX , tumor tissue surround normal tissue . Secondary hypothesis tumor incubate Levulan show great fluorescence untreated tumor tumor incubate vehicle ( placebo application ) . As Institutional Review Boards involve generally desire pilot data adult population first , proceed adult clinical trial portion protocol part 2 . Part 2 use optimum incubation time , one identify part 1 , add dose escalation study amount red light use activate Levulan . Part 3 , pediatric subject , commence future date , pending review initial adult study result .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Subjects NF1 select photodynamic therapy follow criterion . 1 . Age : 18 year old . 2 . NF1 diagnose American Academy Neurology guideline . 3 . Location tumor : cutaneous , trunk limb . 4 . Tumor type : superficial dermal neurofibroma , less equal 4 mm deep . 5 . Growth confirmation : direct measurement dermal neurofibroma , ruler photovolumetric method . 6 . Informed consent subject . 7 . Absence malignancy . 8 . Only failures meet criterion 16 due primary disease disqualify Subjects exclude participation study basis follow : 1 . Life expectancy less 1 year . 2 . Pregnancy . 3 . Inability consent . 4 . Cutaneous photosensitivity wavelength use activate PDT . 5 . A diagnosis porphyria . 6 . Allergy aminolevulinic acid Topical Solution Vehicle component . 7 . Previous chemotherapy within 6 week propose PDT . 8 . Other concurrent tumor therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>